16,667 Hymus Boulevard
30 articles with Valeo Pharma
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®
Valeo Pharma Inc., a Canadian pharmaceutical company, announced that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler.
Valeo Pharma Inc., a Canadian pharmaceutical company, provided an outlook for its second quarter ended April 30th, projecting record revenues and margins.
Valeo Pharma Inc . a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement ("PLA") with the Executive Officer of the Ontario Public Drug Program
Valeo Pharma Inc . (CSE: VPH) a Canadian pharmaceutical company, announced today that it has upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca and Redesca HP
Valeo Pharma Inc . , a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin ("LMWH") biosimilar, for the prevention and treatment of thromboembolic disorders.
Valeo Pharma Inc. Enters into an Agreement for Enerzair & Breezhaler and Atectura Breezhaler in Canada
Valeo to commercialize Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , 2 innovative asthma therapies approved by Health Canada Positions Valeo as one of the leading Canadian Respiratory companies Almost 4 million Canadians afflicted with asthma 1 ; Canadian market for asthma medication exceeds $700M annually 2
Valeo Pharma's Hesperco Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial
[17-February-2021] Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process Hesperidin may help against Covid-19 viral replication Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm
Valeo Pharma Inc . ( CSE: VPH) (OTCQB: VPHIF) (FSE: VP2 ) (" Valeo "), a Canadian pharmaceutical company, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States . "We are pleased to have secured
Valeo Pharma Inc., a Canadian pharmaceutical company, announced that it has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting.
Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has commenced shipping online orders of its unique flavonoid formulation, HespercoTM.
MONTREAL, Sept. 23, 2020 /PRNewswire/ - Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it will report its financial results and highlights for the third quarter ended July 31, 2020 on Tuesday September 29, 2020 after market close.
Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian specialty pharmaceutical company, announced today that the Company has qualified to trade on the OTCQB market in the United States . Valeo's shares have started trading today on the OTCQB under the symbol "VP
Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has received a Natural Product Licence approval from Health Canada authorizing the sale of its bioflavonoid formulation, HespercoTM, in Canada.
Valeo Pharma Has Submitted Hesperco™ Natural Product License Application for Approval to Health Canada
Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
MONTREAL, July 29, 2020 /PRNewswire/ - Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has completed and filed its application to list the Company's Class A shares on the OTCQB market in the United States.
Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it will be presenting at Wall Street Reporter's livestream conference on Wednesday July 29, 2020.
Valeo Pharma Inc. is pleased to announce that it will be presenting at the Bloom Burton & Co. Healthcare Investor Conference to be held April 30-May 1, 2019 in Toronto, Ontario.
Valeo Pharma Inc. a Canadian specialty pharmaceutical company, reported financial results for its first quarter ended January 31, 2019.
Valeo Pharma Inc. reported financial results for its fourth quarter and year ended October 31, 2018. All dollar amounts are in thousands and reported in Canadian dollars, unless otherwise stated.